Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best way to deliver antibiotic combo against superbugs

NCT ID NCT07478484

Disease control Sponsor: Jing Zhou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two different ways of giving a combination of two antibiotics (ceftazidime-avibactam and aztreonam) to treat serious infections caused by bacteria that are resistant to many drugs. The researchers want to see if giving the drugs one after the other works as well as giving them together. The study will include 144 people with infections like pneumonia, urinary tract infections, or bloodstream infections. The goal is to find the safest and most effective way to deliver this treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftazidime-avibactam combined with aztreonam
What this could lead to
If successful, this study could identify the best way to give these two antibiotics together, improving treatment for serious infections that resist many other drugs.
What could go wrong
This is a Phase 4 trial comparing infusion methods, not testing a new drug. The results may not show a clear advantage, and the infections involved are very difficult to treat, so outcomes may still be poor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), or bloodstream infection (BSI); 2. Patients with confirmed infections caused by metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), as determined by genotypic testing using next-generation sequencing (NGS) or carbapenem resistance gene testing; 3. Patients receiving treatment with ceftazidime-avibactam in combination with aztreonam. Exclusion Criteria: 1. Patients aged under 18 years; 2. Patients with known hypersensitivity to ceftazidime, avibactam, aztreonam, or any of the excipients; or those with a history of severe hypersensitivity reactions (e.g., anaphylactic shock, severe skin reactions) to any other β-lactam antibacterial agents (such as penicillins, monobactams, or carbapenems); 3. Pregnant or breastfeeding women; 4. Patients unable to comprehend or comply with the study protocol; 5. Any other condition which, in the investigator's discretion, makes the patient unsuitable for participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aztreonam are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aztreonam Carbapenem-resistant Ceftazidime-avibactam Gram-negative bacterial infection Metallo-Β-lactamase-producing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jing Zhou

    RECRUITING

    Nanjin, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.